C4 Therapeutics, Inc.
CCCC
$2.53
-$0.08-3.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -111.58M | -103.28M | -105.32M | -105.50M | -107.87M |
| Total Depreciation and Amortization | 1.99M | 1.83M | 1.82M | 1.77M | 1.77M |
| Total Amortization of Deferred Charges | -- | -- | -- | 0.00 | 51.00K |
| Total Other Non-Cash Items | 30.33M | 30.65M | 30.69M | 28.87M | 29.10M |
| Change in Net Operating Assets | -8.15M | -9.53M | 7.65M | 3.63M | -868.00K |
| Cash from Operations | -87.41M | -80.32M | -65.16M | -71.23M | -77.81M |
| Capital Expenditure | -168.00K | -180.00K | -180.00K | -341.00K | -954.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.05M | 31.43M | -51.09M | -32.65M | 25.52M |
| Cash from Investing | 81.88M | 31.25M | -51.27M | -33.00M | 24.57M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 0.00 | -11.00M |
| Issuance of Common Stock | 10.41M | 10.54M | 45.15M | 102.71M | 92.42M |
| Repurchase of Common Stock | -240.00K | -240.00K | -194.00K | -194.00K | -125.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 407.00K | 407.00K | 382.00K | 380.00K | 346.00K |
| Cash from Financing | 10.57M | 10.71M | 45.34M | 102.90M | 81.64M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.04M | -38.37M | -71.09M | -1.33M | 28.40M |